FDA Approves Insulin Efsitora Alfa-Gobe, First Once-Weekly Basal Insulin for Type 2 Diabetes

The FDA has approved insulin efsitora alfa-gobe (Onswik, Eli Lilly), a once-weekly basal insulin, as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes, marking the first once-weekly basal insulin to reach the US market in this drug class. The approval, announced September 24, 2026, represents the fourth global regulatory clearance for the agent, following earlier actions by the European Medicines Agency (EMA), Mexico's COFEPRIS, and Japan's PMDA.

"For over a century, Lilly has been developing insulins that transformed diabetes care for millions of people worldwide, but delays in initiating treatment and the burden of daily injections can have a real impact on patients' day-to-day experience managing type 2 diabetes," said Kenneth Custer, PhD, executive vice president and president of Lilly Cardiometabolic Health. The approval is anticipated to reduce the annual injection burden from approximately 365 doses with once-daily basal insulin to 52 doses per year—a reduction of more than 300 injections annually, according to the company.¹

QWINT Phase 3 Program

The FDA approval is grounded in data from the QWINT Phase 3 clinical trial program, which enrolled more than 3,400 adults with type 2 diabetes across four multinational, randomized, open-label, treat-to-target trials conducted between 2022 and 2025.

QWINT-1 (NCT05662332) randomized 795 insulin-naïve participants in the US, Argentina, and Mexico to once-weekly efsitora or once-daily insulin glargine U-100 for 52 weeks. Efsitora was initiated at 100 units and escalated through fixed dosages (150, 250, and 400 units) at four-week intervals until a fasting blood glucose target of 80–130 mg/dL was achieved.³ QWINT-2 (NCT05362058) compared efsitora to insulin degludec U-100 over 52 weeks in 928 insulin-naïve participants across 11 countries, with a secondary analysis designed to assess outcomes in patients concurrently using GLP-1 receptor agonists.⁴ QWINT-3 (NCT05275400) enrolled 986 adults already on basal insulin across 10 countries, comparing efsitora to degludec over 78 weeks, with non-inferiority assessed at week 26.⁵ QWINT-4 (NCT05462756) randomized 730 participants on basal-bolus regimens to efsitora or glargine U-100 for 26 weeks, both administered alongside insulin lispro.⁶

In each trial, the primary endpoint—non-inferior reduction in HbA1c from baseline at either week 26 or week 52—was met versus insulin glargine U-100 or insulin degludec U-100. The overall safety profile of efsitora was reported to be similar to that of the comparator daily basal insulins across all four trials.²⁻⁶

Clinical Context and Unmet Need

Approximately one in eight Americans lives with diabetes, with type 2 diabetes accounting for the large majority of cases.⁷ Globally, more than 510 million people are projected to have type 2 diabetes by 2030, with an estimated 38 million expected to require insulin therapy, according to a microsimulation analysis published in The Lancet Diabetes & Endocrinology.⁸ Despite robust pharmacological options, glycemic targets remain elusive for a substantial proportion of patients, partly due to therapeutic inertia and the perceived or actual burden of daily injectable regimens. A once-weekly dosing schedule may address one component of this barrier, though real-world glycemic outcomes in diverse populations will require longer-term post-marketing evaluation.

Mechanism and Drug Background

Insulin efsitora alfa-gobe is a long-acting basal insulin engineered to maintain stable pharmacokinetic activity over a full seven-day period following subcutaneous injection. It is available in two concentrations via prefilled KwikPen: U-500 (500 units/mL; 1,500 units total) and U-1,000 (1,000 units/mL; 3,000 units total), with dosing increments of 5 and 10 units, respectively. The agent is not approved for use in type 1 diabetes, given the risk of severe hypoglycemia in that population.

The QWINT trials were designed and powered for non-inferiority, not superiority, and used open-label designs—both factors that may limit the strength of conclusions regarding comparative efficacy. Direct head-to-head comparisons with newer basal insulins or combination incretin-based therapies were not the primary focus of the program. Additionally, QWINT-2 included a secondary analysis of patients using GLP-1 receptor agonists, but those data have not yet been fully characterized in the context of the FDA label. Clinicians should note that dosing with the KwikPen differs substantively from other injectable insulin products, with maximum single doses of 400 units (U-500 pen) and 800 units (U-1,000 pen), necessitating careful patient education to prevent dosing errors.

The Onswik KwikPen is expected to be available in the US within the coming months. Long-term data on cardiovascular outcomes, safety in renally impaired patients, and use in pediatric populations have not yet been established.

References

1. Eli Lilly and Company. US Food and Drug Administration (FDA) approves Lilly's Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes [press release]. September 24, 2026. https://investor.lilly.com/news-releases/news-release-details/us-food-and-drug-administration-fda-approves-lillys-onswiktm
2. Onswik (insulin efsitora alfa-gobe). Prescribing Information. Indianapolis, IN: Lilly USA, LLC; 2026.
3. Rosenstock J, Bailey T, Connery L, et al. Weekly fixed-dose insulin efsitora in type 2 diabetes without previous insulin therapy. N Engl J Med. 2025;393(4):325-335. doi:10.1056/NEJMoa2502796
4. Wysham C, Bajaj HS, Del Prato S, et al. Insulin efsitora versus degludec in type 2 diabetes without previous insulin treatment. N Engl J Med. 2024;391(23):2201-2211. doi:10.1056/NEJMoa2403953